Skip to main content

PAPEL DEL SPLICING ALTERNATIVO Y SU (DES)REGULACION EN PATOLOGIAS TUMORALES Y CANCER: POTENCIAL DIAGNOSTICO Y TERAPEUTICO

BFU2013-43282-R

•
Funding agency name Ministerio de Economía y Competitividad
Funding agency acronym MINECO
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2013
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Management unit Secretaría de Estado de Educación, Formación Profesional y Universidades
Beneficiary centre UNIVERSIDAD DE CORDOBA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Helvia. Repositorio Institucional de la Universidad de Córdoba
Publication Artículo científico (JournalArticle)

Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas

  • Luque, Raúl M.
  • Ibáñez-Costa, Alejandro
  • Vieira Neto, Leonardo
  • Taboada, Giselle F
  • Hormaechea-Agulla, Daniel
  • Kasuki, Leandro
  • Venegas-Moreno, Eva
  • Moreno-Carazo, Alberto
  • Gálvez-Moreno, M. Ángeles
  • Soto-Moreno, Alfonso
  • Kineman, Rhonda D
  • Culler, Michael D
  • Gahete Ortiz, Manuel D.
  • Gadelha, Monica R
  • Castaño, Justo P.
The GH/IGF1 response of somatotropinomas to somatostatin analogues (SSA) is associated with their pattern of somatostatin receptor (sst1-sst5) expression. Recently, we demonstrated that expression of a truncated sst5-variant (sst5TMD4) can influence the secretory response of somatotropinomas to SSA-therapy; however, its potential relationship with aggressive features (e.g. invasion/proliferation) is still unknown. Here, we show that sst5TMD4 is present in 50% of non-functioning pituitary-adenomas (NFPA) (n = 30) and 89% of somatotropinomas (n = 36), its expression levels being highest in somatotropinomas > > NFPAs > > > normal pituitaries (negligible expression; n = 8). In somatotropinomas, sst5TMD4 mRNA and protein levels correlated positively, and its expression was directly associated with tumor invasiveness (cavernous/sphenoid sinus), and inversely correlated with age and GH/IGF1 reduction after 3-6 months with octreotide-LAR therapy. GNAS+ somatotropinomas expressed lower sst5TMD4 levels. ROC analysis revealed sst5TMD4 expression as the only marker, within all sst-subtypes, capable to predict tumor invasiveness in somatotropinomas. sst5TMD4 overexpression increased cell viability in cultured somatotropinoma (n = 5). Hence, presence of sst5TMD4 associates with increased aggressive features and worse prognosis in somatotropinomas, thereby providing a potentially useful tool to refine somatotropinoma diagnosis, predict outcome of clinical response to SSA-therapy and develop new therapeutic targets.
Helvia. Repositorio Institucional de la Universidad de Córdoba
Publication Artículo científico (JournalArticle)

Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly

  • Venegas-Moreno, Eva
  • Vázquez Borrego, María del Carmen
  • Dios, Elena
  • Gros-Herguido, Noelia
  • Flores Martínez, Álvaro
  • Rivero-Cortés, Esther
  • Madrazo Atutxa, Ainara M.
  • Japón, Miguel Ángel
  • Luque, Raúl M.
  • Castaño, Justo P.
  • Cano, David A.
  • Soto-Moreno, Alfonso
Acromegaly is a hormonal disorder resulting from excessive growth hormone (GH) secretion frequently produced by pituitary adenomas and consequent increase in insulin-like growth factor 1 (IGF-I). Elevated GH and IGF-I levels result in a wide range of somatic, cardiovascular, endocrine, metabolic and gastrointestinal morbidities. Somatostatin analogues (SSAs) form the basis of medical therapy for acromegaly and are currently used as first-line treatment or as second-line therapy in patients undergoing unsuccessful surgery. However, a considerable percentage of patients do not respond to SSAs treatment. Somatostatin receptors (SSTR1-5) and dopamine receptors (DRD1-5) subtypes play critical roles in the regulation of hormone secretion. These receptors are considered important pharmacological targets to inhibit hormone oversecretion. It has been proposed that decreased expression of SSTRs may be associated with poor response to SSAs. Here, we systematically examine SSTRs and DRDs expression in human somatotroph adenomas by quantitative PCR. We observed an association between the response to SSAs treatment and DRD4, DRD5, SSTR1 and SSTR2 expression. We also examined SSTR expression by immunohistochemistry and found that the immunohistochemical detection of SSTR2 in particular might be a good predictor of response to SSAs.
Helvia. Repositorio Institucional de la Universidad de Córdoba
Publication Artículo científico (JournalArticle)

Association between radiological parameters and clinical and molecular characteristics in human somatotropinomas

  • Alhambra Expósito, María Rosa
  • Ibáñez-Costa, Alejandro
  • Moreno Moreno, Paloma
  • Rivero-Cortés, Esther
  • Vázquez Borrego, María del Carmen
  • Blanco-Acevedo, Cristóbal
  • Toledano-Delgado, Álvaro
  • Lombardo Galera, María Sagrario
  • Vallejo-Casas, Juan-Antonio
  • Gahete Ortiz, Manuel D.
  • Castaño, Justo P.
  • Gálvez-Moreno, M. Ángeles
  • Luque, Raúl M.
Acromegaly is a rare but severe disease, originated in 95% of cases by a growth hormone-secreting adenoma (somatotropinoma) in the pituitary. Magnetic resonance imaging (MRI) is a non-invasive technique used for the diagnosis and prognosis of pituitary tumours. The aim of this study was to determine whether the use of T2-weighted signal intensity at MRI could help to improve the characterisation of somatotropinomas, by analysing its relationship with clinical/molecular features. An observational study was implemented in a cohort of 22 patients (mean age = 42.1 ± 17.2 years; 59% women; 95% size>10 mm). Suprasellar-extended somatotropinomas presented larger diameters vs. non-extended tumours. T2-imaging revealed that 59% of tumours were hyperintense and 41% isointense adenomas, wherein hyperintense were more invasive (according to Knosp-score) than isointense adenomas. A higher proportion of hyperintense somatotropinomas presented extrasellar-growth, suprasellar-growth and invasion of the cavernous sinus compared to isointense adenomas. Interestingly, somatostatin receptor-3 and dopamine receptor-5 (DRD5) expression levels were associated with extrasellar and/or suprasellar extension. Additionally, DRD5 was also higher in hyperintense adenomas and its expression was directly correlated with Knosp-score and with tumour diameter. Hence, T2-weighted MRI on somatotropinomas represents a potential tool to refine their diagnosis and prognosis, and could support the election of preoperative treatment, when required.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Molecular characterization of growth hormone-producing tumors in the GC rat model of acromegaly

  • Martín-Rodríguez, Juan Francisco
  • Muñoz-Bravo, José Luis
  • Fernández-Maza, Laura
  • Balcerzyk, Marcin
  • Venegas Moreno, Eva
  • Soto-Moreno, Alfonso
  • Leal Cerro, Alfonso
  • Cano González, David A.
et al., Acromegaly is a disorder resulting from excessive production of growth hormone (GH) and consequent increase of insulin-like growth factor 1 (IGF-I), most frequently caused by pituitary adenomas. Elevated GH and IGF-I levels results in wide range of somatic, cardiovascular, endocrine, metabolic, and gastrointestinal morbidities. Subcutaneous implantation of the GH-secreting GC cell line in rats leads to the formation of tumors. GC tumor-bearing rats develop characteristics that resemble human acromegaly including gigantism and visceromegaly. However, GC tumors remain poorly characterized at a molecular level. In the present work, we report a detailed histological and molecular characterization of GC tumors using immunohistochemistry, molecular biology and imaging techniques. GC tumors display histopathological and molecular features of human GH-producing tumors, including hormone production, cell architecture, senescence activation and alterations in cell cycle gene expression. Furthermore, GC tumors cells displayed sensitivity to somatostatin analogues, drugs that are currently used in the treatment of human GH-producing adenomas, thus supporting the GC tumor model as a translational tool to evaluate therapeutic agents. The information obtained would help to maximize the usefulness of the GC rat model for research and preclinical studies in GH-secreting tumors., D.A.C. was supported by the Nicolás Monardes program of the Andalusian Ministry of Health (C-0015-2014) and by a grant from the Andalusian Ministry of Science and Innovation (CTS-7478). A.S-M and A.L.C were supported by grants from the ISCIII-Subdirección General de Evaluación y Fomento de la Investigación co-funded with Fondos FEDER (PI12/0143 and PI13/02043, respectively) and the Andalusian Regional Government (CTS-444) and a grant from Pfizer Spain. R.L.C. was supported by a grant from Andalusian Ministry of Health (PI0302-2012). R.M.L. was supported by grants from Proyecto de Investigación en Salud (FIS) PI13-00651 (funded by Instituto de Salud Carlos III), CTS-1406, PI-0639-2012, BIO-0139 (funded by Junta de Andalucía) and by Ayuda Merck Serono 2013. J. P. C. was funded by a grant (BFU2013-43282-R) from Ministerio de Economía y Competitividad. CIBER is an initiative of Instituto de Salud Carlos III, Ministerio de Sanidad, Servicios Sociales e Igualdad, Spain. J.F.M.R. is supported by the “Sara Borrell” program from the Instituto de Salud Carlos III. R.M. Luque and J.P. Castaño have received grants and lecture fees from Ipsen and Novartis. E. Venegas-Moreno and A. Soto-Moreno received grants and lecture fees from Ipsen, Novartis and Pfizer. A. Leal-Cerro received grants from Novartis and Pfizer. David Cano received a grant from Novartis., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The truncated somatostatin receptor sst5TMD4 stimulates the angiogenic process and is associated to lymphatic metastasis and disease-free survival in breast cancer patients

  • Gahete, Manuel D.
  • Durán-Prado, Mario
  • Hergueta-Redondo, Marta
  • Moreno-Bueno, Gema
  • Luque, Raúl M.
  • Castaño, Justo P.
Gahete et al., The truncated somatostatin receptor sst5TMD4 is associated with poor prognosis in breast cancer and increases breast cancer cell malignancy. Here, we examined the cellular/molecular mechanisms underlying this association, aiming to identify new molecular tools to improve diagnosis, prognosis or therapy. A gene expression array comparing sst5TMD4 stably-transfected MCF-7 cells and their controls (empty-plasmid) revealed the existence of profound alterations in the expression of genes involved in key tumoral processes, such as cell survival or angiogenesis. Moreover, sst5TMD4- overexpressing MCF-7 and MDA-MB-231 cells demonstrated increased expression/ production of pro-angiogenic factors and enhanced capacity to form mammospheres. Consistently, sst5TMD4-expressing MCF-7 cells induced xenografted tumors with higher VEGF levels and elevated number of blood vessels. Importantly, sst5TMD4 was expressed in a subset of breast cancers, where it correlated with angiogenic markers, lymphatic metastasis, and reduced disease-free survival. These results, coupled to our previous data, support a relevant role of sst5TMD4 in the angiogenic process and reinforce the role of sst5TMD4 in breast cancer malignancy and metastatic potential, supporting its possible utility to develop new molecular biomarkers and drug therapies for these tumors., This work has been funded by the following grants: BIO-0139, CTS-1406, PI-0639-2012, BFU2010-19300, BFU2013-43282-R, PI13/00651 and CIBERobn (to RML and JPC); PI-0541-2013 and “Miguel Servet” program (to MDG); PI13/00132, RETICC RD12/0036/0007, S2010/BMD-2303 (to GMB). CIBER is an initiative of Instituto de Salud Carlos III, Ministerio de Sanidad, Servicios Sociales e Igualdad, Spain., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

In1-ghrelin splicing variant is associated with reduced disease-free survival of breast cancer patients and increases malignancy of breast cancer cells lines

  • Rincón-Fernández, David
  • Culler, Michael D.
  • Tsomaia, Natia
  • Moreno-Bueno, Gema
  • Luque, Raúl M.
  • Gahete, Manuel D.
  • Castaño, Justo P.
Ghrelin gene generates several variants that regulate multiple pathophysiological functions, including tumor-related processes. In1-ghrelin is a splicing variant that was previously shown to be overexpressed in breast cancer (BCa), where it correlated with proliferation markers; however, its possible association with clinical outcome of BCa patients and underlying mechanisms are still unknown. To address this issue, expression levels and clinical associations of In1-ghrelin were analyzed in a cohort of 117 BCa samples. Additionally, a battery of cellular and molecular assays was implemented using two BCa cell lines (MCF-7 and MDA-MB-231), wherein the role of In1-ghrelin on proliferation, migration, dedifferentiation and signaling pathways was explored. The results generated revealed that high expression of In1-ghrelin in BCa samples was associated with lymph node metastasis and reduced disease-free survival. Indeed, In1-ghrelin overexpression stimulated proliferation and migration in MCF-7 and MDA-MB-231 cells. Similar results were found by treating MDA-MB-231 and MCF-7 with In1-ghrelin-derived peptides. Conversely, In1-ghrelin silencing decreased proliferation and migration capacities of MDA-MB-231. Furthermore, In1-ghrelin (but not ghrelin) overexpression increased the capacity to form mammospheres in both cell lines. These effects could be associated with activation of MAPK-ERK, Jag1/Notch, Wnt/β-catenin and/or TGF-β1 pathways. Altogether, our data indicate that In1-ghrelin could play relevant functional roles in the regulation of BCa development and progression and may provide insights to identify novel biomarkers and new therapeutic approaches for this pathology., BIO-0139, CTS-1406, PI-639–2012, PI-0541-2013 (Junta de Andalucia), BFU2013-43282-R, BFU2016-80360-R (MINECO), PI16/00264, CP15/00156 and “Miguel Servet” Program [Proyectos de Investigación en Salud FIS, funded by Instituto de Salud Carlos III and co-funded by European Union (ERDF/ESF, “Investing in your future”)], and CIBERobn (to RML, MDG and JPC); PI16/00134 [Proyectos de Investigación en Salud FIS, funded by Instituto de Salud Carlos III and co-funded by European Union (ERDF/ESF, “Investing in your future”)] and CB16/12/00295 (CIBERONC) (to GMB). CIBER is an initiative of Instituto de Salud Carlos III, Ministerio de Sanidad, Servicios Sociales e Igualdad, Spain. Tissue samples were obtained with the support of MD Anderson Foundation Biobank (record number B.0000745, ISCIII National Biobank Record)., Peer reviewed